Angina News and Research

RSS

Angina is chest pain or discomfort that occurs when an area of your heart muscle doesn't get enough oxygen-rich blood. Angina may feel like pressure or squeezing in your chest. The pain also may occur in your shoulders, arms, neck, jaw, or back. It can feel like indigestion.

Sensitive troponin assays improve clinical outcome and cardiac patient management

Research presented this week at the International Federation of Clinical Chemistry Congress and Laboratory Medicine showed that using a lower diagnostic threshold for troponin improves clinical outcomes and patient survival in patients with suspected acute coronary syndromes.

19 May 2011

CryoLife acquires Cardiogenesis

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that it has successfully completed its acquisition of Cardiogenesis Corporation.

17 May 2011

Many herbal medicines banned under EU directives

According to the new EU rules that came into force over the weekend, hundreds of herbal remedies are now banned. The laws are aimed at protecting consumers from potentially damaging “traditional” medicines.

1 May 2011

Takeda, Affymax announce additional peginesatide Phase 3 study results in dialysis patients

Affymax, Inc. and Takeda Pharmaceutical Company Limited, today announced results of additional analyses from two Phase 3 studies of the investigational agent, peginesatide in chronic renal failure patients on dialysis with anemia.

29 Apr 2011

Neovasc 2010 consolidated net loss decreases to $2,630,885

Neovasc Inc., today announced financial results for the year ended December 31, 2010.

27 Apr 2011

Study: HIV infection linked to increased risk of heart failure

Patients with HIV infection without a prior history of coronary heart disease may be at a higher risk of developing heart failure, according to a report in the April 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

26 Apr 2011

Longitudinal displacement in carotid artery reflects both degree of atherosclerosis in artery and heart function

How your carotid artery moves can reveal your risk of a future heart attack, and it is now possible to study this vessel aspect in more detail thanks to a new technique which could eventually be used to identify patients with suspected coronary artery disease, reveals a thesis from the University of Gothenburg, Sweden.

12 Apr 2011

New risk calculator predicts risk of postoperative complications for bariatric surgery patients

A new risk calculator can predict the risk of postoperative complications occurring for individual bariatric surgery patients, according to a study published in the March issue of the Journal of the American College of Surgeons. The risk calculator will help in surgical decision-making and will help patients better understand what they can expect during recovery in order to prepare for a bariatric operation.

5 Apr 2011

$Ranolazine is an effective treatment for patients with refractory angina$

Ranolazine is an effective treatment for patients with refractory angina

Ranolazine is an effective anti-anginal therapy in patients with refractory angina; however, at one year only 59 percent of patients remained on the drug, according to a scientific poster that will be presented at the American College of Cardiology Scientific Sessions in New Orleans, April 1-3.

5 Apr 2011

Both radial and femoral approaches are safe and effective for angioplasty

In the future you may hear the doctor say: "Give me your arm and I'll do some heart surgery."

5 Apr 2011

Regado's REG1 system Phase 2b trial results presented at i2 Summit

Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced today the primary results of the RADAR Phase 2b clinical trial of the company's lead product, the anticoagulation system REG1, at the i2 Summit during the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans, LA.

4 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

ACCF, AHA guidelines recognize Effient as Class I treatment option for patients with ACS-PCI

Oral antiplatelet therapy Effient has been added to the updated clinical practice guidelines as a Class I recommended treatment option for patients undergoing percutaneous coronary intervention fter experiencing heart-related chest pain at rest or non-ST segment elevation myocardial infarction.

30 Mar 2011

CryoLife to acquire Cardiogenesis

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, and Cardiogenesis Corporation, a leading developer of surgical products used in the treatment of patients with refractory angina resulting from diffuse coronary artery disease, today announced that the boards of directors of both companies have approved a definitive agreement under which CryoLife will acquire all of the outstanding shares of Cardiogenesis for $0.457 per share.

29 Mar 2011

Improved technology is improving outcomes for cardiac stent patients

While coronary artery bypass surgery has long been the standard treatment for patients with the most extensive forms of coronary artery disease, the results of a recent study by an international team of researchers suggests that advances in technology appear to be narrowing the "benefit gap" between the two approaches. The results of the study appear in the March 17, 2011 issue of the New England Journal of Medicine.

28 Mar 2011

Nurse staffing levels, safety net status both factors in patient outcomes

A new study finds that higher nurse staffing levels can lead to better patient outcomes. However, the study also found this to not always be the case at safety net hospitals. Meanwhile, the Connecticut Mirror reports on hospitals' efforts to reduce readmissions. And, in other news, new research has found that patients are less likely to fill prescriptions when doctors specify brand names instead of allowing generic substitutions.

28 Mar 2011

More sensitive test to detect protein troponin associated with increased diagnosis of heart attacks

In patients with a suspected acute coronary syndrome (ACS; such as heart attack or unstable angina), use of a more sensitive test to detect the protein troponin in blood was associated with increased diagnosis of a heart attack and improved identification of patients at high risk of another heart attack and death in the following year, according to a study in the March 23/30 issue of JAMA.

23 Mar 2011

Shire announces FDA PDUFA date for FIRAZYR NDA in treatment of acute attacks of hereditary angioedema

Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of August 25, 2011 for the review of the New Drug Application (NDA) for FIRAZYR(R) (icatibant) for the treatment of acute attacks (Types I and II) of hereditary angioedema (HAE). This 6 month review timeline is consistent with review as a Class II resubmission.

21 Mar 2011

Journal of Clinical Lipidology publishes LipoScience LDL particle study results against CVD

LipoScience, Inc., a highly innovative diagnostic company that is advancing patient care by developing high value proprietary blood tests using nuclear magnetic resonance technology, today announced publication of a clinical study in the Journal of Clinical Lipidology demonstrating that in many people, low density lipoprotein cholesterol is a less accurate predictor of cardiovascular disease events than LDL particle number.

19 Mar 2011

Cellpraxis, USF Health, UNIFESP present and evaluate ReACT results at scientific meeting

Cellpraxis, USF Health and UNIFESP presented and evaluated the clinical results of an innovative therapy for Refractory Angina patients in a scientific meeting and workshop in São Paulo, Brazil.

15 Mar 2011

Angina News and Research

Further Reading

Sensitive troponin assays improve clinical outcome and cardiac patient management

CryoLife acquires Cardiogenesis

Many herbal medicines banned under EU directives

Takeda, Affymax announce additional peginesatide Phase 3 study results in dialysis patients

Neovasc 2010 consolidated net loss decreases to $2,630,885

Study: HIV infection linked to increased risk of heart failure

Longitudinal displacement in carotid artery reflects both degree of atherosclerosis in artery and heart function

New risk calculator predicts risk of postoperative complications for bariatric surgery patients

Ranolazine is an effective treatment for patients with refractory angina

Both radial and femoral approaches are safe and effective for angioplasty

Regado's REG1 system Phase 2b trial results presented at i2 Summit

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

ACCF, AHA guidelines recognize Effient as Class I treatment option for patients with ACS-PCI

CryoLife to acquire Cardiogenesis

Improved technology is improving outcomes for cardiac stent patients

Nurse staffing levels, safety net status both factors in patient outcomes

More sensitive test to detect protein troponin associated with increased diagnosis of heart attacks

Shire announces FDA PDUFA date for FIRAZYR NDA in treatment of acute attacks of hereditary angioedema

Journal of Clinical Lipidology publishes LipoScience LDL particle study results against CVD

Cellpraxis, USF Health, UNIFESP present and evaluate ReACT results at scientific meeting

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News